The effects of GLP-1 analogues on pre-diabetes of the children

Zhou,Qing‑Xia; Wang,Zi‑Yu; Zhao,Hua‑Feng; Wang,Shan

doi:10.3892/etm.2017.4129

The effects of GLP-1 analogues on pre-diabetes of the children

Authors:
- Qing‑Xia Zhou
- Zi‑Yu Wang
- Hua‑Feng Zhao
- Shan Wang
View Affiliations

Affiliations: Department of Pediatrics, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China, Department of Radiology, Yidu Central Hospital of Weifang, Weifang, Shandong 262500, P.R. China, Department of Pediatrics, People's Hospital of Shouguang City, Shouguang, Shandong 262700, P.R. China
Published online on: February 16, 2017 https://doi.org/10.3892/etm.2017.4129
Pages: 1426-1430
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the study was to evaluate the clinical efficacy of glucagon‑like peptide-1 (GLP-1) analogues in children of pre-diabetes to delay or reverse the development of pre‑diabetes into the state of diabetes by early intervention. Prospective and randomized controlled clinical trials were performed in 42 cases of newly diagnosed pre‑diabetes in children. The sample size was randomly divided into the two groups. The first group included 21 subjects comprising the lifestyle intervention group, i.e., control group, and the second group included 21 subjects comprising the lifestyle intervention+GLP‑1 analogues liraglutide group, i.e., observation group. Interventions carried out lasted 3 months. A review of intervention was carried out at 1 month and after 3 months. Medical examinations were carried out at the the time following diagnosis with pre‑diabetes and after the intervention of 3 months. The medical test examinations included the fasting blood glucose (FPG), 2‑hour postprandial blood glucose (2hPG), detection of glycated hemoglobin A1c (HbA1C), total cholesterol (TC), triglyceride (TG), low‑density lipoprotein cholesterol (LDL‑C), high‑density lipoprotein cholesterol (HDL‑C), body mass index (BMI), insulin resistance (IR) and the islet cell functions. After 1 month of intervention, the observation group exhibited a better control on FPG and 2hPG compared with the control group (P<0.05). After 3 months of the intervention, FPG and 2hPG levels of the observation group were significantly lower than those of the control group (P<0.01). The levels of HbA1C, TC, TG, LDL‑C, HDL‑C, and BMI of the observation group were statistically better controlled, when compared with the control group after the intervention of 3 months. The IR index of the observation group was significantly decreased compared to that of the control group (P<0.05) and the islet function index of the β-cell of the observation group showed statistically higher values than that of the control group (P<0.05). In conclusion, GLP‑1 analogues are a better regulator of blood sugar levels, effectively improve lipid profile, body mass, IR and islet β-cell function. Furthermore, GLP‑1 analogues opens up a new way to intervene pre-diabetes in children.

View Figures

View References

1	American Diabetes Association, . Standards of medical care in diabetes - 2010. Diabetes Care. 33 Suppl 1:S11–S61. 2010. View Article : Google Scholar : PubMed/NCBI
2	Amed S, Daneman D, Mahmud FH and Hamilton J: Type 2 diabetes in children and adolescents. Expert Rev Cardiovasc Ther. 8:393–406. 2010. View Article : Google Scholar : PubMed/NCBI
3	American Diabetes Association, . Diagnosis and classification of diabetes mellitus. Diabetes Care. 35 Suppl 1:S64–S71. 2012. View Article : Google Scholar : PubMed/NCBI
4	Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:412–419. 1985. View Article : Google Scholar : PubMed/NCBI
5	Haslam DW and James WP: Obesity. Lancet. 366:1197–1209. 2005. View Article : Google Scholar : PubMed/NCBI
6	Rush EC, Plank LD, Mitchelson E and Laulu MS: Central obesity and risk for type 2 diabetes in Maori, Pacific, and European young men in New Zealand. Food Nutr Bull. 23 Suppl 3:82–86. 2002.PubMed/NCBI
7	Brosnan CA, Upchurch S and Schreiner B: Type 2 diabetes in children and adolescents: An emerging disease. J Pediatr Health Care. 15:187–193. 2001. View Article : Google Scholar : PubMed/NCBI
8	Craig ME, Hattersley A and Donaghue KC: Definition, epidemiology and classification of diabetes in children and adolescents. Pediatr Diabetes. 10 Suppl 12:3–12. 2009. View Article : Google Scholar : PubMed/NCBI
9	Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, et al: China National Diabetes and Metabolic Disorders Study Group: Prevalence of diabetes among men and women in China. N Engl J Med. 25:1090–1101. 2010. View Article : Google Scholar
10	Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N and Rojanasakul A: Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynaecol Obstet. 75:177–184. 2001. View Article : Google Scholar : PubMed/NCBI
11	D'Alessio DA and Vahl TP: Glucagon-like peptide 1 Evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab. 286:E882–E890. 2004. View Article : Google Scholar : PubMed/NCBI
12	Theodorakis MJ, Carlson O, Michopoulos S, Doyle ME, Juhaszova M, Petraki K and Egan JM: Human duodenal enteroendocrine cells: Source of both incretin peptides, GLP-1 and GIP. Am J Physiol Endocrinol Metab. 290:E550–E559. 2006. View Article : Google Scholar : PubMed/NCBI
13	Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B and Holst JJ: Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 44:1126–1131. 1995. View Article : Google Scholar : PubMed/NCBI
14	Buse JB, Henry RR, Han J, Kim DD, Fineman MS and Baron AD; Exenatide-113 Clinical Study Group, : Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 27:2628–2635. 2004. View Article : Google Scholar : PubMed/NCBI
15	DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS and Baron AD: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 28:1092–1100. 2005. View Article : Google Scholar : PubMed/NCBI
16	Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS and Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 28:1083–1091. 2005. View Article : Google Scholar : PubMed/NCBI
17	Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, et al: One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: A randomized, controlled trial. Diabetes Care. 32:762–768. 2009. View Article : Google Scholar : PubMed/NCBI
18	Russell-Jones D: Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol. 15:137–140. 2009. View Article : Google Scholar
19	Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rössner S, et al: NN8022-1807 Investigators: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 36:843–854. 2012. View Article : Google Scholar : PubMed/NCBI
20	Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD and S; LEAD-1 SU study group Colagiuri: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 26:268–278. 2009. View Article : Google Scholar : PubMed/NCBI
21	Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M and Matthews DR; LEAD-2 Study Group, : Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 32:84–90. 2009. View Article : Google Scholar : PubMed/NCBI
22	Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M and Bode B; LEAD-3 (Mono) Study Group, : Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 373:473–481. 2009. View Article : Google Scholar : PubMed/NCBI
23	Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M and Blonde L: LEAD-4 Study Investigators: Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 32:1224–1230. 2009. View Article : Google Scholar : PubMed/NCBI
24	Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM and Simó R; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group: Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia. 52:2046–2055. 2009. View Article : Google Scholar : PubMed/NCBI
25	Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M and Blonde L; LEAD-6 Study Group, : Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 374:39–47. 2009. View Article : Google Scholar : PubMed/NCBI